questionsmedicales.fr
Technologie, industrie et agriculture
Industrie
Secteur secondaire
Industrie pharmaceutique
Industrie pharmaceutique : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Essais cliniques
Efficacité des médicaments
Essais cliniques
Phase III
Critères d'inclusion
Essais cliniques
Effets secondaires
Pharmacovigilance
Symptômes
5
Réaction médicamenteuse
Effets indésirables
Allergie médicamenteuse
Réactions allergiques
Overdose
Intoxication médicamenteuse
Interaction médicamenteuse
Effets indésirables
Effets secondaires
Pharmacovigilance
Prévention
5
Effets indésirables
Pharmacovigilance
Prescription médicale
Pratiques cliniques
Sensibilisation
Éducation à la santé
Interactions médicamenteuses
Conseils médicaux
Polymédication
Gestion des médicaments
Traitements
5
Développement de médicaments
Essais cliniques
Médicaments génériques
Pharmacie
Thérapie ciblée
Oncologie
Médicaments orphelins
Maladies rares
Mise sur le marché
Réglementation des médicaments
Complications
5
Complications médicamenteuses
Effets indésirables
Réaction allergique
Urgences médicales
Surdosage
Intoxication médicamenteuse
Médicaments anticancéreux
Effets indésirables
Facteurs de risque
5
Facteurs de risque
Effets indésirables
Alcool
Interactions médicamenteuses
Médicaments à risque
Personnes âgées
Maladies chroniques
Pharmacologie
Automédication
Risques médicaux
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Industrie pharmaceutique : Questions médicales les plus fréquentes",
"headline": "Industrie pharmaceutique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Industrie pharmaceutique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-13",
"dateModified": "2025-04-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Industrie pharmaceutique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Secteur secondaire",
"url": "https://questionsmedicales.fr/mesh/D066192",
"about": {
"@type": "MedicalCondition",
"name": "Secteur secondaire",
"code": {
"@type": "MedicalCode",
"code": "D066192",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "J01.576.655"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Médicament orphelin",
"alternateName": "Orphan Drug Production",
"url": "https://questionsmedicales.fr/mesh/D009965",
"about": {
"@type": "MedicalCondition",
"name": "Médicament orphelin",
"code": {
"@type": "MedicalCode",
"code": "D009965",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "J01.576.655.750.600"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Industrie pharmaceutique",
"alternateName": "Drug Industry",
"code": {
"@type": "MedicalCode",
"code": "D004345",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Beatriz G de la Torre",
"url": "https://questionsmedicales.fr/author/Beatriz%20G%20de%20la%20Torre",
"affiliation": {
"@type": "Organization",
"name": "KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa."
}
},
{
"@type": "Person",
"name": "Fernando Albericio",
"url": "https://questionsmedicales.fr/author/Fernando%20Albericio",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa."
}
},
{
"@type": "Person",
"name": "Christophe Tistaert",
"url": "https://questionsmedicales.fr/author/Christophe%20Tistaert",
"affiliation": {
"@type": "Organization",
"name": "Small Molecules Pharmaceutical Development, Drug Product Development, Biopharmaceutics, Janssen Research and Development, Beerse, Belgium."
}
},
{
"@type": "Person",
"name": "Tycho Heimbach",
"url": "https://questionsmedicales.fr/author/Tycho%20Heimbach",
"affiliation": {
"@type": "Organization",
"name": "Department of PK Sciences, PBPK and Biopharmaceutics Section, Novartis Institutes for BioMedical Research, East Hanover, New Jersey 07936."
}
},
{
"@type": "Person",
"name": "Joel Lexchin",
"url": "https://questionsmedicales.fr/author/Joel%20Lexchin",
"affiliation": {
"@type": "Organization",
"name": "School of Health Policy and Management, York University, Toronto, ON, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Is connective tissue massage effective in individuals with fibromyalgia?",
"datePublished": "2023-12-27",
"url": "https://questionsmedicales.fr/article/38763557",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jbmt.2023.09.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pharmacological Therapies for Connective Tissue Fibrosis in Orthopaedics.",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/35970181",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03635465221116358"
}
},
{
"@type": "ScholarlyArticle",
"name": "Developmental Foot Deformities in Patients with Connective Tissue Disorders.",
"datePublished": "2023-02-17",
"url": "https://questionsmedicales.fr/article/36800486",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2106/JBJS.RVW.22.00219"
}
},
{
"@type": "ScholarlyArticle",
"name": "The association between keratoconus and systemic manifestations of connective tissue hyperlaxity.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37479535",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clae.2023.101892"
}
},
{
"@type": "ScholarlyArticle",
"name": "A new conceptual model for anorexia nervosa: A role for connective tissue?",
"datePublished": "2024-02-19",
"url": "https://questionsmedicales.fr/article/38372082",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/eat.24172"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Technologie, industrie et agriculture",
"item": "https://questionsmedicales.fr/mesh/D013676"
},
{
"@type": "ListItem",
"position": 3,
"name": "Industrie",
"item": "https://questionsmedicales.fr/mesh/D007221"
},
{
"@type": "ListItem",
"position": 4,
"name": "Secteur secondaire",
"item": "https://questionsmedicales.fr/mesh/D066192"
},
{
"@type": "ListItem",
"position": 5,
"name": "Industrie pharmaceutique",
"item": "https://questionsmedicales.fr/mesh/D004345"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Industrie pharmaceutique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Industrie pharmaceutique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Industrie pharmaceutique",
"description": "Comment évaluer l'efficacité d'un médicament ?\nQu'est-ce qu'une étude de phase III ?\nQuels sont les critères d'inclusion dans un essai ?\nComment sont mesurés les effets secondaires ?\nQu'est-ce qu'un placebo ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Connective+Tissue#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Industrie pharmaceutique",
"description": "Quels symptômes peuvent indiquer une réaction médicamenteuse ?\nComment reconnaître une allergie médicamenteuse ?\nQuels signes d'overdose sont fréquents ?\nQuels symptômes d'une interaction médicamenteuse ?\nComment identifier un effet secondaire rare ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Connective+Tissue#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Industrie pharmaceutique",
"description": "Comment prévenir les effets indésirables des médicaments ?\nQuelles sont les bonnes pratiques de prescription ?\nComment sensibiliser aux risques médicamenteux ?\nQuels conseils pour éviter les interactions médicamenteuses ?\nComment gérer les prescriptions multiples ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Connective+Tissue#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Industrie pharmaceutique",
"description": "Comment sont développés les nouveaux médicaments ?\nQu'est-ce qu'un médicament générique ?\nComment fonctionne la thérapie ciblée ?\nQu'est-ce qu'un médicament orphelin ?\nComment se déroule la mise sur le marché d'un médicament ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Connective+Tissue#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Industrie pharmaceutique",
"description": "Quelles complications peuvent survenir avec les médicaments ?\nComment gérer une réaction allergique grave ?\nQuels sont les risques de surdosage ?\nComment prévenir les complications liées aux traitements ?\nQuelles sont les complications des médicaments anticancéreux ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Connective+Tissue#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Industrie pharmaceutique",
"description": "Quels facteurs augmentent le risque d'effets secondaires ?\nComment l'alcool influence-t-il les médicaments ?\nQuels médicaments sont à risque pour les personnes âgées ?\nComment les maladies chroniques affectent-elles la médication ?\nQuels sont les risques liés à l'automédication ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Connective+Tissue#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un médicament ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des essais cliniques et des études de marché."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une étude de phase III ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une étude qui teste l'efficacité d'un médicament sur un grand nombre de patients."
}
},
{
"@type": "Question",
"name": "Quels sont les critères d'inclusion dans un essai ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères d'inclusion définissent les caractéristiques des participants éligibles."
}
},
{
"@type": "Question",
"name": "Comment sont mesurés les effets secondaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont mesurés par des rapports de patients et des études post-commercialisation."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un placebo ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un placebo est un traitement inactif utilisé comme référence dans les essais cliniques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une réaction médicamenteuse ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des éruptions cutanées, des nausées ou des vertiges peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une allergie médicamenteuse ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les allergies se manifestent par des démangeaisons, des rougeurs ou un gonflement."
}
},
{
"@type": "Question",
"name": "Quels signes d'overdose sont fréquents ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, somnolence, et troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une interaction médicamenteuse ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des vertiges, des palpitations ou des troubles digestifs peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment identifier un effet secondaire rare ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires rares sont souvent identifiés par des études de pharmacovigilance."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables des médicaments ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une prescription appropriée et une surveillance des patients."
}
},
{
"@type": "Question",
"name": "Quelles sont les bonnes pratiques de prescription ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bonnes pratiques incluent l'évaluation des antécédents médicaux et la communication avec le patient."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser aux risques médicamenteux ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La sensibilisation se fait par des campagnes d'information et des formations pour les professionnels."
}
},
{
"@type": "Question",
"name": "Quels conseils pour éviter les interactions médicamenteuses ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé de toujours informer le médecin de tous les médicaments pris, y compris les OTC."
}
},
{
"@type": "Question",
"name": "Comment gérer les prescriptions multiples ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique une coordination entre les différents prescripteurs et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Comment sont développés les nouveaux médicaments ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les nouveaux médicaments sont développés par la recherche, les essais cliniques et l'approbation réglementaire."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un médicament générique ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un médicament générique est une version d'un médicament de marque, généralement moins coûteuse."
}
},
{
"@type": "Question",
"name": "Comment fonctionne la thérapie ciblée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie ciblée agit sur des molécules spécifiques impliquées dans la maladie."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un médicament orphelin ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un médicament orphelin est destiné à traiter des maladies rares, souvent sans alternatives."
}
},
{
"@type": "Question",
"name": "Comment se déroule la mise sur le marché d'un médicament ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La mise sur le marché nécessite des essais cliniques, une évaluation réglementaire et une approbation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les médicaments ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des réactions allergiques, des surdosages et des interactions."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction allergique grave ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réaction allergique grave nécessite une intervention médicale immédiate, comme l'adrénaline."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de surdosage ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le surdosage peut entraîner des dommages organiques, des troubles neurologiques ou la mort."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux traitements ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un suivi régulier et une évaluation des effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications des médicaments anticancéreux ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections, des nausées et des troubles sanguins."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, le poids, les maladies préexistantes et les interactions médicamenteuses augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment l'alcool influence-t-il les médicaments ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'alcool peut intensifier les effets des médicaments, augmentant le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont à risque pour les personnes âgées ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médicaments à risque incluent les sédatifs, les anticoagulants et certains analgésiques."
}
},
{
"@type": "Question",
"name": "Comment les maladies chroniques affectent-elles la médication ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies chroniques peuvent modifier la réponse aux médicaments et augmenter les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quels sont les risques liés à l'automédication ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'automédication peut entraîner des interactions, des surdosages et des retards de traitement."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 07/04/2025
Contenu vérifié selon les dernières recommandations médicales
6 publications dans cette catégorie
Affiliations :
KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
6 publications dans cette catégorie
Affiliations :
School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.
3 publications dans cette catégorie
Affiliations :
Small Molecules Pharmaceutical Development, Drug Product Development, Biopharmaceutics, Janssen Research and Development, Beerse, Belgium.
Publications dans "Industrie pharmaceutique" :
3 publications dans cette catégorie
Affiliations :
Department of PK Sciences, PBPK and Biopharmaceutics Section, Novartis Institutes for BioMedical Research, East Hanover, New Jersey 07936.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Health Policy and Management, York University, Toronto, ON, Canada.
Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Journalism and Communication, Carleton University, Ottawa, ON, Canada.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Public Policy & Administration, Carleton University, Ottawa, ON, Canada.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Public Policy & Administration, Carleton University, Ottawa, ON, Canada.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Pharmaceutical Sciences, Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Medicinal Science and Technology, GlaxoSmithKline R&D, Ware, Hertfordshire, UK.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, New Jersey 07033. Electronic address: filippos_kesisoglou@merck.com.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Pfizer, Inc, BioTherapeutics PharmSci, 1 Burtt Road, Andover MA 01810, USA.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Genentech (A Member of the Roche Group), Pharmaceutical Development, 1 DNA Way, South San Francisco, CA 94080, USA.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Pfizer PGRD, Sandwich CT13 9NJ, UK.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
AstraZeneca UK Limited, Macclesfield SK10 2NA, UK.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Pharmacy and Biomedical Sciences, University of Portsmouth, St. Michael's Building, White Swan Road, Portsmouth PO1 2DT, UK.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Department of Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California, USA.
Publications dans "Industrie pharmaceutique" :
1 publication dans cette catégorie
Affiliations :
Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
Publications dans "Industrie pharmaceutique" :
1 publication dans cette catégorie
Affiliations :
Department of Poultry Science, University of Arkansas, Fayetteville, AR, USA.
Publications dans "Industrie pharmaceutique" :
1 publication dans cette catégorie
Affiliations :
Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany. paul.selzer@boehringer-ingelheim.com.
Publications dans "Industrie pharmaceutique" :
The aim of the study was to examine the effectiveness of Clinical Pilates exercises and connective tissue massage (CTM) in individuals with Fibromyalgia (FM) on pain, disease impact, functional status...
32 women were randomly divided into two groups as intervention gorup (CTM + Clinical Pilates exercises, n = 15, mean age = 48.80 ± 7.48) and control gorup (Clinical Pilates exercises, n = 17, mean age...
When the pre-treatment and post-treatment results are analyzed; significant difference was observed in PLI (p = 0.007; effect size 1.273), FIQ (p = 0.004; effect size 0.987), SF-36 physical component ...
CTM can be effective in reducing the number of painful areas in addition to the positive effects of clinical Pilates exercises in women with FM....
Fibrosis is a common and debilitating pathological process that affects many organ systems and contributes to connective tissue disorders in orthopaedics. Tendons heal after acute and chronic injury t...
Foot deformities make up a large percentage of all orthopaedic complaints in patients with Down syndrome, Marfan syndrome, Ehlers-Danlos syndrome, Larsen syndrome, and osteogenesis imperfecta....
Some common causes of foot deformities in these conditions include increased ligament laxity, hypotonia, and hypermobility of the joints....
Treatment options for syndromic foot deformities include the use of foot orthoses, physical therapy, bracing, and various surgical procedures....
There is limited evidence supporting the use of surgical intervention to correct foot deformities associated with Down syndrome, Marfan syndrome, Ehlers-Danlos syndrome, Larsen syndrome, and osteogene...
To evaluate the correlation between keratoconus and systemic manifestations of tissue hyperlaxity in the general population....
In this population based cross-sectional study 940,763 medical records of Israeli adolescents and young adults in military service were reviewed. Demographic and medical data were extracted. The preva...
Overall 938,411 adolescents and adults were included. Mean age was 17.55 ± 1.50 years, and 40.70% were female. Keratoconus was documented in 1,529 cases, with a prevalence of 0.16%. Compared to the ge...
In this large cohort of adolescents and young adults, an association was found between keratoconus and connective tissue hyperlaxity manifestations involving the knees, feet, spine and abdomen. These ...
The etiology of anorexia nervosa (AN) remains to be fully elucidated, and current theories also fail to account for the direct effect of starvation on the health of the organs and tissues, specificall...
Multiple cases of autoimmune and autoinflammatory diseases after COVID-19 have been reported. However, their incidences and risks have rarely been quantified....
To investigate the incidences and risks of autoimmune and autoinflammatory connective tissue disorders after COVID-19....
This was a retrospective population-based study conducted between October 8, 2020, and December 31, 2021, that used nationwide data from the Korea Disease Control and Prevention Agency COVID-19 Nation...
Receipt of diagnosis of COVID-19....
The primary outcomes were the incidence and risk of autoimmune and autoinflammatory connective tissue disorders following COVID-19. A total of 32 covariates, including demographics, socioeconomic stat...
A total of 354 527 individuals with COVID-19 (mean [SD] age, 52.24 [15.55] years; 179 041 women [50.50%]) and 6 134 940 controls (mean [SD] age, 52.05 [15.63] years; 3 074 573 women [50.12%]) were inc...
In this retrospective cohort study, COVID-19 was associated with a substantial risk for autoimmune and autoinflammatory connective tissue disorders, indicating that long-term management of patients wi...
Dental implants are now one of the most useful therapies worldwide with higher rates of success from simple to complex cases, but also, with different results regarding the esthetics, cost and long-te...
Anecdotally, fibromyalgia syndrome (FMS) and connective tissue disorders (hypermobile Ehlers-Danlos Syndrome (hEDS), Hypermobility Spectrum disorders (HSD) and Generalized Joint Hypermobility (GJH)) m...
MEDLINE (via EBSCO host) was systematically searched. Observational research (case-control or single group) studies were considered for inclusion, where adults screened for hEDS/HSD/GJH and FMS were c...
The review included eleven studies: nine case-control studies and two single group studies. The prevalence of concomitant diagnosis of hEDS/HSD and FMS ranged from 68%-88.9% and from 8.0 to 64.2% for ...
There may be overlapping symptomatology and diagnostic prevalence of FMS and hEDS/HSD/GJH. Clinicians should consider both diagnoses to ensure appropriate diagnosis and management....
The durability of reimplanted myxomatous aortic valves in root replacements for patients with connective tissue disorders (CTD) is unclear; therefore, we sought to evaluate the long-term resilience of...
From January 1980 to January 2020, 214 patients with CTD and 645 without CTD underwent primary, elective aortic valve reimplantation operations at Cleveland Clinic. The CTD cohort included 164 (77%) w...
In the CTD cohort, there were no operative mortalities (30-day or in-hospital), 1 (0.47%) stroke, and 1 (0.47%) early in-hospital reoperation for valve dysfunction. Ten-year prevalence of no aortic re...
Aortic valve reimplantation is a durable operation in patients with CTD and root aneurysms. These patients do not experience early degeneration of their reimplanted aortic valves....
Lesion formation after soft tissue gingival grafting is a rare but challenging clinical scenario to manage. This report presents a unique case of cyst formation after connective tissue grafting. All p...